News
EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural
Sensorion Announces Its Participation in Several Investor Conferences to be Held in March
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Agilent Announces Cash Dividend of 24.8 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of
ICON Reports Fourth Quarter and Full Year 2024 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and full year ended December 31
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00
Premier, Inc. Enters Into $200 Million Accelerated Share Repurchase Program
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that it has entered into accelerated share repurchase agreements with JPMorgan Chase Bank
Sensorion Announces Its Participation In Several Congresses To Be Held In March
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Siegfried reports continued profitable growth fueled by strong underlying business
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech releases Universal Registration Document 2024
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On February 12
Chemed Corporation Declares Quarterly Dividend of 50 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on March 14, 2025, to
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights:
-
Revenue grew 8%
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth
Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program
Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will
EQS-Adhoc: Eckert & Ziegler Affected by Cyber Attack
EQS-News: Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and